logo
Share SHARE
FONT-SIZE Plus   Neg

Eli Lilly Amd Kowa Pharmaceuticals Reveal Positive Results Of PREVAIL US Study

Eli Lilly and Company (LLY) and Kowa Pharmaceuticals America Inc., Thursday jointly announced the results of the PREVAIL U.S. study which evaluated the efficacy of LIVALO 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

The two companies noted that PREVAIL U.S. was designed as a superiority trial for the primary endpoint, LDL-C reduction, and evaluated the adult population age 18-80 with primary hyperlipidemia or mixed dyslipidemia. LIVALO 4 mg showed superior LDL-C reduction compared with pravastatin 40 mg after 12 weeks of therapy.

"We are very pleased with the results of PREVAIL U.S., which are consistent with previous trials evaluating LIVALO's effect on LDL-C reduction," said Dr. Craig Sponseller, Vice President of Medical Affairs at Kowa Pharmaceuticals America, Inc. "Although the clinical relevance of these data require further study, these data are important as they represent the first of such particle analysis with LIVALO."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
German telecom giant Deutsche Telekom AG reported Wednesday that its first-quarter net profit quadrupled on hefty stake sale gain. Revenues also increased on US strength, while domestic revenues were weak. Royal Dutch Shell reported Wednesday a pre-tax loss in its first quarter, while CCS earnings plunged from last year mainly on weak revenues. Oil and gas production increased but that was offset by lower prices. Further, the company announced dividend, and warned on second-quarter earnings. Shares of French lender Societe Generale SA were gaining around 4 percent in the early morning trading in Paris after the company reported Wednesday higher profit in its first quarter, even as net banking income was weak. Looking ahead, Chief Executive Officer Frédéric Oudéa said, "With a sound balance sheet and robust solvency ratios, the Group is confident about its outlook for 2016,..
comments powered by Disqus
Follow RTT